Factors Influencing Adalimumab Treatment Response in Patients with Rheumatoid Arthritis: The Future of Clinical Expertise:

Samer Imad Mohammed; Ali Lateef  Jasim; Mohammad Yawuz Jamal; Saad Abdulrahman Hussain

doi:10.54133/ajms.v5i.232

Authors

Samer Imad Mohammed Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0001-7073-9976
Ali Lateef Jasim Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0003-2473-0799
Mohammad Yawuz Jamal Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0003-0878-8384
Saad Abdulrahman Hussain Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Rafidain University College, Baghdad 10052, Iraq https://orcid.org/0000-0002-1909-417X

DOI:

https://doi.org/10.54133/ajms.v5i.232

Keywords:

Adalimumab, Rheumatoid arthritis, Effectiveness and safety, TNF-α receptors

Abstract

Rheumatoid arthritis (RA) is characterized by persistent joint inflammation, which is a defining feature of this chronic inflammatory condition. Considerable advancements have been made in the field of disease-modifying anti-rheumatic medicines (DMARDs), which effectively mitigate inflammation and forestall further joint deterioration. Anti-tumor necrosis factor-alpha (TNF-α) drugs, which are a class of biological DMARDs (bDMARDs), have been efficaciously employed in the treatment of RA in recent times Adalimumab, a TNF inhibitor, has demonstrated significant efficacy in reducing disease symptoms and halting disease progression in patients with RA. However, its use is associated with major side effects and high costs. In addition, ongoing advancements in therapeutic development have resulted in the production of medications that exhibit enhanced efficacy and safety characteristics. However, further investigation is required before RA can be deemed a manageable pathology. This review presents an analysis of the utilization of adalimumab for the treatment of RA by synthesizing information from relevant literature and emphasizing its effectiveness and safety to improve overall outcomes along with potential cost reductions for patients with RA.

Downloads

Download data is not yet available.

References

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038. doi: 10.1016/S0140-6736(16)30173-8.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960-977. doi: 10.1136/annrheumdis-2016-210715.

Koga T, Kawakami A, Tsokos GC. Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Clin Immunol. 2021;225:108680. doi: 10.1016/j.clim.2021.108680.

Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149-160. doi: 10.1002/path.2287.

Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: Prospective cohort study. BMJ. 2019;364:l7. doi: 10.1136/bmj.l67.

Genovese MC, Fleischmann R, Kivitz A, Lee EB, Hoogstraten HV, Kimura T, et al. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Res Ther. 2020;22:139. doi: 10.1186/s13075-020-02194-z.

Dantes E, Tofolean DE, Fildan AP, Craciun L, Dumea E, Tofolean I, et al. Lethal disseminated tuberculosis in patients under biological treatment - Two clinical cases and a short review. J Int Med Res. 2018;46:2961-2969. doi: 10.1177/0300060518771273.

Papadopoulos CG, Gartzonikas IK, Pappa TK, Markatseli TE, Migkos MP, Voulgari PV, et al. Eight-year survival study of first-line tumour necrosis factor alpha inhibitors in rheumatoid arthritis: Real-world data from a university centre registry. Rheumatol Adv Pract. 2019;3:rkz007. doi: 10.1093/rap/rkz007.

Bongartz T, Sutton AJ, Sweeting MJ. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285. doi: 10.1001/jama.295.19.2275.

Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum. 2017;47:149-156. doi: 10.1016/j.semarthrit.2017.02.007.

Machado MA, Moura CS, Ferré F, Bernatsky S, Rahme E, Acurcio Fde A. Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev Saude Publica. 2016;50:50. doi: 10.1590/S1518-8787.2016050006265.

Yokoyama S, Ishii Y, Masuda J. Persistence and safety of golimumab in elderly patients with rheumatoid arthritis and renal dysfunction in a real-world setting. Drugs Real World Outcomes. 2023;10(1):51-60. doi: 10.1007/s40801-022-00338-y.

Atreya R, Neurath MF. IL-23 blockade in anti-TNF refractory IBD: From mechanisms to clinical reality. J Crohns Colitis. 2022;16(Suppl. 2):ii54-ii63. doi: 10.1093/ecco-jcc/jjac007.

Michielsens CAJ, Boers N, den Broeder N, Wenink MH, van der Maas A, Mahler EAM, et al. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomized, non-inferiority trial. Trials. 2020;21(1):90. doi: 10.1186/s13063-019-4000-5.

Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-alpha therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int. 2022;42(9):1493-1511. doi: 10.1007/s00296-022-05136-x.

Brankov N, Jacob SE. Adalimumab. J Dermatol Nurses Assoc. 2016;8(3):216-220. doi: 10.1097/JDN.0000000000000229.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45. doi.: 10.1002/art.10697.

Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74(3):513-518. doi: 10.1136/annrheumdis-2013-204172.

Cacciapaglia F, Venerito V, Stano S, Fornaro M, Lopalco G, Iannone F. Comparison of adalimumab to other targeted therapies in rheumatoid arthritis: Results from systematic literature review and meta-analysis. J Pers Med. 2022;12(3):353. doi: 10.3390/jpm12030353.

Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2022;8(1):e002012. doi: 10.1136/rmdopen-2021-002012.

Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford). 2011;50(1):196-203. doi: 10.1093/rheumatology/keq325.

Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1. doi: 10.1186/ar2666.

van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104-109. doi: 10.1136/annrheumdis-2012-201445.

Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum. 2006;54(1):76-81. doi: 10.1002/art.21528.

Fletcher A, Lassere M, March L, Hill C, Barrett C, Carroll G, et al. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatology (Oxford). 2022;61(10):3939-3951. doi: 10.1093/rheumatology/keac048.

Blüml S, Scheinecker C, Smolen JS, Redlich K. Targeting TNF receptors in rheumatoid arthritis. Int. Immunol. 2012;24:275-281. doi: 10.1093/intimm/dxs047.

Chen Y, Yuan J, Cai Z, Ma Y. Efficacy of tumor necrosis factor inhibitor combined with intra-articular injection of triamcinolone acetonide in the treatment of refractory rheumatoid arthritis synovitis: a retrospective study. Clin Rheumatol. 2023. doi: 10.1007/s10067-023-06530-x.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639. doi: 10.1002/acr.21641.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573.

Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, et al. Long-term effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014;41(1):5-14. doi: 10.3899/jrheum.130543.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700-1721. doi: 10.1016/s0149-2918(03)80164-9.

Navarro-Millán I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR. Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerability. PLoS One. 2016;11(3):e0149781. doi: 10.1371/journal.pone.0149781.

Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Annals of the rheumatic diseases. 2006;65(6):753-759. doi: 10.1136/ard.2005.044404.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921-926. doi: 10.1136/ard.2006.065615.

Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford). 2012;51(Suppl 5):v22-30. doi: 10.1093/rheumatology/kes115.

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24(3):390-398. doi: 10.3109/14397595.2013.843760.

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22(4):498-508. doi: 10.1007/s10165-011-0541-5.

Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):e16. doi: 10.1136/annrheumdis-2013-203893.

Burmester GR, Matucci-Cerinic M, Mariette X, Navarro-Blasco F, Kary S, Unnebrink K, et al. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther. 2014;16(1):R24. doi: 10.1186/ar4452.

Haraoui B, Cividino A, Stewart J, Guérette B, Keystone EC. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study. BMC Musculoskelet Disord. 2011;12:261. doi: 10.1186/1471-2474-12-261.

Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716-3725. doi: 10.1182/blood-2008-09-179754.

Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447-457. doi: 10.1016/j.semarthrit.2013.07.011.

Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844. doi: 10.3389/fimmu.2021.755844.

Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272. doi: 10.1186/s13075-016-1170-3.

Huang JY, Leong PY, Ker A, Chen HH, Wei JC. The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study. Int J Rheum Dis. 2022;25(11):1295-1305. doi: 10.1111/1756-185X.14423.

Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimizing treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114101. doi: 10.1177/1759720X221114101.

Fischer R, Kontermann RE, Pfizenmaier K. Selective targeting of TNF receptors as a novel therapeutic approach. Front Cell Dev Biol. 2020;8:401. doi: 10.3389/fcell.2020.00401.

Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-inhibitors. Front Immunol. 2020;11:312. doi: 10.3389/fimmu.2020.00312.

Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213-222. doi: 10.1093/rheumatology/ket260.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-1468. doi: 10.1001/jama.2011.406.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69(5):817-821. doi: 10.1136/ard.2009.112847.

Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914-1915. doi: 10.1136/annrheumdis-2012-201544.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22):1594-1602. doi: 10.1056/NEJM200011303432202.

Ebell M, Kripke C. Adalimumab for rheumatoid arthritis? Am Fam Physician. 2006;73(3):435-436.

Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1):45. doi: 10.1186/s13045-020-00876-4.

Julià M, Guilabert A, Lozano F, Suarez-Casasús B, Moreno N, Carrascosa JM, et al. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol. 2013;149(9):1033-1039. doi: 10.1001/jamadermatol.2013.4632.

Lu J, Spencer M, Zou Z, Traver M, Brzostowski J, Sun PD. FcγRI FG-loop functions as a pH sensitive switch for IgG binding and release. Front Immunol. 2023;14:1100499. doi: 10.3389/fimmu.2023.1100499.

Morales-Lara MJ, Conesa-Zamora P, García-Simón MS, Pedrero F, Santaclara V, Perez-Guillermo M, et al. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scand J Rheumatol. 2010;39(6):518-520. doi: 10.3109/03009741003781969.

Jezernik G, Gorenjak M, Potočnik U. Gene ontology analysis highlights biological processes influencing non-response to anti-TNF therapy in rheumatoid arthritis. Biomedicines. 2022;10(8):1808. doi: 10.3390/biomedicines10081808.

Kim J, Lee JY, Kim HG, Kwak MW, Kang TH. Fc receptor variants and disease: A crucial factor to consider in the antibody therapeutics in clinic. Int J Mol Sci. 2021;22(17):9489. doi: 10.3390/ijms22179489.

Márquez Pete N, Maldonado Montoro MDM, Pérez Ramírez C, Martínez Martínez F, Martínez de la Plata JE, Daddaoua A, et al. Influence of the FCGR2A rs1801274 and FCGR3A rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis. J Pers Med. 2021;11(6):573. doi: 10.3390/jpm11060573.

Li X, Kimberly RP. Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets. 2014;18(3):335-350. doi: 10.1517/14728222.2014.877891.

Ravaei A, Pulsatelli L, Assirelli E, Ciaffi J, Meliconi R, Salvarani C, et al. MTHFR c.665C>T and c.1298A>C polymorphisms in tailoring personalized anti-TNF-α therapy for rheumatoid arthritis. Int J Mol Sci. 2023;24(4):4110. doi: 10.3390/ijms24044110.

Dávila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW, et al. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics. 2015;16(4):373-381. doi: 10.2217/pgs.14.178.

Montes A, Perez-Pampin E, Narváez J, Cañete JD, Navarro-Sarabia F, Moreira V, et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics. 2014;24(5):238-245. doi: 10.1097/FPC.0000000000000042.

Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005;52(9):2693-2696. doi: 10.1002/art.21266.

Smiljanovic B, Grün JR, Biesen R, Schulte-Wrede U, Baumgrass R, Stuhlmüller B, et al. The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med (Berl). 2012;90(11):1295-1309. doi: 10.1007/s00109-012-0907-y.

Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, et al. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2010;87(3):311-321. doi: 10.1038/clpt.2009.244.

Yoon BR, Yoo SJ, Choi Yh, Chung YH, Kim J, Yoo IS, Kang SW, et al. Functional phenotype of synovial monocytes modulating inflammatory T-cell responses in rheumatoid arthritis (RA). PLoS One. 2014;9(10):e109775. doi: 10.1371/journal.pone.0109775.

Sugimoto C, Hasegawa A, Saito Y, Fukuyo Y, Chiu KB, Cai Y, Breed MW, et al. Differentiation kinetics of blood monocytes and dendritic cells in Macaques: Insights to understanding human myeloid cell development. J Immunol. 2015;195(4):1774-1781. doi: 10.4049/jimmunol.1500522.

Loke P, Niewold TB. By CyTOF: Heterogeneity of human monocytes. Arterioscler Thromb Vasc Biol. 2017;37(8):1423-1424. doi: 10.1161/ATVBAHA.117.309645.

Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376-381. doi: 10.1038/nature12873.

Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet. 2007;80(5):867-875. doi: 10.1086/516736.

Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004;75(3):504-507. doi: 10.1086/423790.

Abbasifard M, Imani D, Bagheri-Hosseinabadi Z. PTPN22 gene polymorphism and susceptibility to rheumatoid arthritis (RA): Updated systematic review and meta-analysis. J Gene Med. 2020;22(9):e3204. doi: 10.1002/jgm.3204.

Diaz-Gallo LM, Martin J. PTPN22 splice forms: a new role in rheumatoid arthritis. Genome Med. 2012;4:13. doi: 10.1186/gm312.

Tizaoui K, Terrazzino S, Cargnin S, Lee KH, Gauckler P, Li H, et al. The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review. Semin Arthritis Rheum. 2021;51(3):513-522. doi: 10.1016/j.semarthrit.2021.03.004.

Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):69-74. doi: 10.1136/ard.2007.084715.

Gao S, Liang W, Xu T, Xun C, Cao R, Deng Q, et al. Associations of tumor necrosis factor alpha gene polymorphisms and ankylosing spondylitis susceptibility: A meta-analysis based on 35 case-control studies. Immunological Invest. 2021;51(4):859-882. doi: 10.1080/08820139.2021.1882485.

Bergman MJ, Kivitz AJ, Pappas DA, Kremer JM, Zhang L, Jeter A, et al. Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis. Rheumatol Ther. 2020;7(4):775-792. doi: 10.1007/s40744-020-00226-3.

Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180-210. doi: 10.1159/000289205.

Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6(1):75-92. doi: 10.1038/nrd2196.

Lim SH, Kim K, Choi CI. Pharmacogenomics of monoclonal antibodies for the treatment of rheumatoid arthritis. J Pers Med. 2022;12(8):1265. doi: 10.3390/jpm12081265.

Miler M, Nikolac Gabaj N, Ćelap I, Grazio S, Tomašić V, Bišćanin A, et al. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy. Rheumatol Int. 2021;41(12):2195-2203. doi: 10.1007/s00296-021-05016-w.

Hadinedoushan H, Noorbakhsh P, Soleymani-Salehabadi H. Tumor necrosis factor alpha gene polymorphism and association with its serum level in Iranian population with rheumatoid arthritis. Arch Rheumatol. 2016;31(4):306-313. doi: 10.5606/ArchRheumatol.2016.5907.

Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, Vieira Maroun S, Arias Santiago S, Ramírez Tortosa MC, et al. Clinical application of pharmacogenetic markers in the treatment of dermatologic pathologies. Pharmaceuticals (Basel). 2021;14(9):905. doi: 10.3390/ph14090905.

Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol. 2006;35(6):435-440. doi: 10.1080/03009740600904284.

Seitz M, Wirthmüller U, Möller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46(1):93-96. doi: 10.1093/rheumatology/kel175.

O'Rielly DD, Roslin NM, Beyene J, Pope A, Rahman P. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009;9(3):161-167. doi: 10.1038/tpj.2009.7.

Saddala MS, Huang H. Identification of novel inhibitors for TNFα, TNFR1 and TNFα-TNFR1 complex using pharmacophore-based approaches. J Transl Med. 2019;17(1):215. doi: 10.1186/s12967-019-1965-5.

Chen W, Xu H, Wang X, Gu J, Xiong H, Shi Y. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis. Int Immunopharmacol. 2015;28(1):146-153. doi: 10.1016/j.intimp.2015.05.049.

Prieto-Pérez R, Cabaleiro T, Daudén E, Abad-Santos F. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J. 2013;13(4):297-305. doi: 10.1038/tpj.2012.53.

Ruiz A, Palacios Y, Garcia I, Chavez-Galan L. Transmembrane TNF and its receptors TNFR1 and TNFR2 in mycobacterial infections. Int J Mol Sci. 2021;22(11):5461. doi: 10.3390/ijms22115461.

El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression. Springerplus. 2016;5(1):1508. doi: 10.1186/s40064-016-3197-y.

Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri FF, et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol Int. 2008;28(9):901-908. doi: 10.1007/s00296-008-0552-5.

Canault M, Leroyer AS, Peiretti F, Lesèche G, Tedgui A, Bonardo B, et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol. 2007;171(5):1713-1723. doi: 10.2353/ajpath.2007.070021.

Sethi JK, Hotamisligil GS. Metabolic messengers: tumour necrosis factor. Nat Metab. 2021;3(10):1302-1312. doi: 10.1038/s42255-021-00470-z.

Ben-Baruch A. Tumor necrosis factor α: Taking a personalized road in cancer therapy. Front Immunol. 2022;13:903679. doi: 10.3389/fimmu.2022.903679.

Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF targeting. Int J Mol Sci. 2018;19(5):1442. doi: 10.3390/ijms19051442.

Pojskic L, Gavrankapetanovic I, Lojo-Kadric N, Hadziselimovic R, Bajrovic K. A genotyping assay for missense mutation in WISP3 gene associated with childhood onset pseudorheumatoid arthropathy. J Health Sci. 2015;5(2):59-64. doi: 10.17532/jhsci.2015.241.

Curtis JR, Hobar C, Hansbrough K. Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. Curr Med Res Opin. 2011;27(1):71-78. doi: 10.1185/03007995.2010.534959.

Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008;67(4):478-484. doi: 10.1136/ard.2007.074104.

Canhão H, Rodrigues AM, Santos MJ, Carmona-Fernandes D, Bettencourt BF, Cui J, et al. TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. Biomed Res Int. 2015;2015:490295. doi: 10.1155/2015/490295.

Ochi S, Saito K, Mizoguchi F, Kato S, Tanaka Y. Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. Arthritis Res Ther. 2020;22(1):41. doi: 10.1186/s13075-020-2122-5.

Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signaling pathways. Ann Rheum Dis. 2010;69(7):1315-1320. doi: 10.1136/ard.2009.117309.

Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human antitumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563-2571.

Popescu CC, Mogoșan CD, Enache L, Codreanu C. Comparison of efficacy and safety of original and biosimilar adalimumab in active rheumatoid arthritis in a real-world national cohort. Medicina (Kaunas). 2022;58(12):1851. doi: 10.3390/medicina58121851.

Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34(5):1040-1050.